Skip to main content

POTENCIAL DE LOS CARDIOMIOCITOS DERIVADOS DE CELULAS PLURIPOTENTES INDUCIDAS (IPS) EN LA FISIOPATOLOGIA Y REGENERACION CARDIACA

SAF2014-59892-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy

  • Roura, Santiago
  • Gálvez-Montón, Carolina
  • Gonzalo-Calvo, David de
  • Gámez Valero, Ana
  • Gastelurrutia, Paloma
  • Revuelta-López, Elena
  • Prat-Vidal, Cristina
  • Soler-Botija, Carolina
  • Llucià‐Valldeperas, Aida
  • Perea‐Gil, Isaac
  • Iborra‐Egea, Oriol
  • Borràs, Francesc E.
  • Lupón, Josep
  • Llorente-Cortés, Vicenta
  • Bayés Genís, Antoni
Idiopathic dilated cardiomyopathy (IDCM) is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, andlow-density lipoprotein receptor-related protein 1 (LRP1) has been linked to the underlying molecular basis of the disease. This study comparedcirculating levels of soluble LRP1 (sLRP1) in IDCM patients and healthy controls and elucidated whether sLRP1 is exported out of the myocardiumthrough extracellular vesicles (EVs) to gain a better understanding of the pathogenesis of the disease. LRP1achain expression was analysed insamples collected from the left ventricles of explanted hearts using immunohistochemistry. sLRP1 concentrations were determined in platelet-freeplasma by enzyme-linked immunosorbent assay. Plasma-derived EVs were extracted by size-exclusion chromatography (SEC) and characterizedby nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (CD9, CD81) and myocardial (caveolin-3) proteins and LRP1achain were assessed in SEC fractions by flow cytometry. LRP1achain was preferably localized to blood vessels in IDCMcompared to control myocardium. Circulating sLRP1 was increased in IDCM patients. CD9- and CD81-positive fractions enriched with membranevesicles with the expected size and morphology were isolated from both groups. The LRP1achain was not present in these SEC fractions, whichwere also positive for caveolin-3. The increase in circulating sLRP1 in IDCM patients may be clinically valuable. Although EVs do not contribute tohigher sLRP1 levels in IDCM, a comprehensive analysis of EV content would provide further insights into the search for novel blood markers, This work was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892-R), the Ministerio de Econom ıa yCompetitividad (Juan de la Cierva, JCI-2012-14025), Fundacio La MARATO de TV3 (201502, 201516, 201521_10), the Fundaci o Daniel Bravo Andreu, the Sociedad Española de Cardiología, the Societat Catalana de Cardiologia, the Generalitat de Catalunya (SGR 2014,CERCA Programme), and the Fundacio Bancaria La Caixa. This workwas also funded by the Red de Terapia Celular–TerCel (RD16/0011/0006), the CIBER Cardiovascular–(CB16/11/00403) and Fondo deInvestigaci on Sanitaria, Instituto de Salud Carlos III (FIS PI14/01682,FIS PI14/01729 and CD14/00109) as part of the Plan Nacional deI+D+I cofounded by ISCIII-Sudirecci on General de Evaluaci on y elFondo Europeo de Desarrollo Regional (FEDER), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure

  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Martínez, Jaume Barallat
  • Pastor Ferrer, Maria Cruz
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Zamora, Elisabet|||0000-0001-5317-7481
  • Sanchis, Juan|||0000-0003-0797-8709
  • Rosés, Josep Lupón
Despite advances in pharmacologic therapy and devices, patients with heart failure (HF) continue to have significant rehospitalization rates and risk prediction remains challenging. We sought to explore the value of a multi-biomarker panel [including NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical assessment for long-term prediction of recurrent hospitalizations in HF. NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) levels were measured in 891 consecutive ambulatory HF patients. The independent association between the multi-biomarker panel and recurrent hospitalizations was assessed through a multivariable negative binomial regression and expressed as incidence rates ratios. McFadden pseudo- R 2 and goodness-of-fit measures were also used. The total number of unplanned hospitalizations [all-cause, cardiovascular (CV)-, and HF-related] were selected as the primary endpoints. At a mean follow-up of 4.2 ± 2.1 years, 1623 all-cause hospitalizations in 498 patients (55.9%), 710 CV-related hospitalizations in 331 patients (37.2%), and 444 HF-related hospitalizations in 214 patients (24.1%) were registered. The crude incidence of all-cause, CV-, and HF-related recurrent hospitalizations was significantly higher for patients with the multi-biomarker panel above the cut-point (hs-TnT.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble 1 in idiopathic dilated cardiomyopathy

  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Valero, Ana Gámez
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Soler Botija, Carolina
  • Llucià-Valldeperas, Aida
  • Perea Gil, Isaac
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Lupón, Josep|||0000-0002-5601-9611
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Idiopathic dilated cardiomyopathy () is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, and low-density lipoprotein receptor-related protein 1 (1) has been linked to the underlying molecular basis of the disease. This study compared circulating levels of soluble 1 (1) in patients and healthy controls and elucidated whether 1 is exported out of the myocardium through extracellular vesicles (s) to gain a better understanding of the pathogenesis of the disease. 1 α chain expression was analysed in samples collected from the left ventricles of explanted hearts using immunohistochemistry. 1 concentrations were determined in platelet-free plasma by enzyme-linked immunosorbent assay. Plasma-derived s were extracted by size-exclusion chromatography () and characterized by nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (9, 81) and myocardial (caveolin-3) proteins and 1 α chain were assessed in fractions by flow cytometry. 1 α chain was preferably localized to blood vessels in compared to control myocardium. Circulating 1 was increased in patients. 9- and 81-positive fractions enriched with membrane vesicles with the expected size and morphology were isolated from both groups. The 1 α chain was not present in these fractions, which were also positive for caveolin-3. The increase in circulating 1 in patients may be clinically valuable. Although s do not contribute to higher 1 levels in , a comprehensive analysis of content would provide further insights into the search for novel blood markers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells in vitro and in silico

  • Llucià-Valldeperas, Aida
  • Bragos, Ramon|||0000-0002-1373-1588
  • Soler Botija, Carolina
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Perea Gil, Isaac
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Mechanical conditioning is incompletely characterized for stimulating therapeutic cells within the physiological range. We sought to unravel the mechanism of action underlying mechanical conditioning of adipose tissue-derived progenitor cells (ATDPCs), both in vitro and in silico. Cardiac ATDPCs, grown on 3 different patterned surfaces, were mechanically stretched for 7 days at 1 Hz. A custom-designed, magnet-based, mechanical stimulator device was developed to apply ~10% mechanical stretching to monolayer cell cultures. Gene and protein analyses were performed for each cell type and condition. Cell supernatants were also collected to analyze secreted proteins and construct an artificial neural network. Gene and protein modulations were different for each surface pattern. After mechanostimulation, cardiac ATDPCs increased the expression of structural genes and there was a rising trend on cardiac transcription factors. Finally, secretome analyses revealed upregulation of proteins associated with both myocardial infarction and cardiac regeneration, such as regulators of the immune response, angiogenesis or cell adhesion. To conclude, mechanical conditioning of cardiac ATDPCs enhanced the expression of early and late cardiac genes in vitro. Additionally, in silico analyses of secreted proteins showed that mechanical stimulation of cardiac ATDPCs was highly associated with myocardial infarction and repair.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function

  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rudilla, F..
  • Llucià-Valldeperas, Aida
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Díaz-Güemes, Idoia
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissue-derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Pujal, Josep Maria
  • Aran, Gemma|||0000-0003-2005-8843
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Undesired immune responses have drastically hampered outcomes after allogeneic organ transplantation and cell therapy, and also lead to inflammatory diseases and autoimmunity. Umbilical cord mesenchymal stem cells (UCMSCs) have powerful regenerative and immunomodulatory potential, and their secreted extracellular vesicles (EVs) are envisaged as a promising natural source of nanoparticles to increase outcomes in organ transplantation and control inflammatory diseases. However, poor EV preparations containing highly-abundant soluble proteins may mask genuine vesicular-associated functions and provide misleading data. Here, we used Size-Exclusion Chromatography (SEC) to successfully isolate EVs from UCMSCs-conditioned medium. These vesicles were defined as positive for CD9, CD63, CD73 and CD90, and their size and morphology characterized by NTA and cryo-EM. Their immunomodulatory potential was determined in polyclonal T cell proliferation assays, analysis of cytokine profiles and in the skewing of monocyte polarization. In sharp contrast to the non-EV containing fractions, to the complete conditioned medium and to ultracentrifuged pellet, SEC-purified EVs from UCMSCs inhibited T cell proliferation, resembling the effect of parental UCMSCs. Moreover, while SEC-EVs did not induce cytokine response, the non-EV fractions, conditioned medium and ultracentrifuged pellet promoted the secretion of pro-inflammatory cytokines by polyclonally stimulated T cells and supported Th17 polarization. In contrast, EVs did not induce monocyte polarization, but the non-EV fraction induced CD163 and CD206 expression and TNF-α production in monocytes. These findings increase the growing evidence confirming that EVs are an active component of MSC's paracrine immunosuppressive function and affirm their potential for therapeutics in nanomedicine. In addition, our results highlight the importance of well-purified and defined preparations of MSC-derived EVs to achieve the immunosuppressive effect.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mesenchymal stem cells induce expression of cD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively. This shifts the pro-inflammatory milieu induced by extracellular ATP to the anti- inflammatory regulation by Ado. Mesenchymal stem cells (MSCs) have potent immunomodulatory capabilities, including monocyte modulation toward an anti-inflammatory phenotype aiding tissue repair. In vitro, we observed that human cardiac adipose tissue-derived MSCs (cATMSCs) and umbilical cord MSCs similarly polarize monocytes toward a regulatory M2 phenotype, which maintained the expression of CD39 and induced expression of CD73 in a cell contact dependent fashion, correlating with increased functional activity. In addition, the local treatment with porcine cATMSCs using an engineered bioactive graft promoted the in vivo CD73 expression on host monocytes in a swine model of myocardial infarction. Our results suggest the upregulation of ectonucleotidases on MSC-conditioned monocytes as an effective mechanism to amplify the long-lasting immunomodulatory and healing effects of MSCs delivery.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Persistent chest pain after recovery of COVID-19, microvascular disease-related angina?

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Head-to-head comparison of two engineered cardiac grafts for myocardial repair, From scaffold characterization to pre-clinical testing

  • Perea Gil, Isaac
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Jorba, Ignasi
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Roura, Santiago|||0000-0003-4063-9661
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Farré, Ramon|||0000-0002-9084-7824
  • Navajas, Daniel|||0000-0001-7150-9363
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac tissue engineering, which combines cells and supportive scaffolds, is an emerging treatment for restoring cardiac function after myocardial infarction (MI), although, the optimal construct remains a challenge. We developed two engineered cardiac grafts, based on decellularized scaffolds from myocardial and pericardial tissues and repopulated them with adipose tissue mesenchymal stem cells (ATMSCs). The structure, macromechanical and micromechanical scaffold properties were preserved upon the decellularization and recellularization processes, except for recellularized myocardium micromechanics that was ∼2-fold stiffer than native tissue and decellularized scaffolds. Proteome characterization of the two acellular matrices showed enrichment of matrisome proteins and major cardiac extracellular matrix components, considerably higher for the recellularized pericardium. Moreover, the pericardial scaffold demonstrated better cell penetrance and retention, as well as a bigger pore size. Both engineered cardiac grafts were further evaluated in pre-clinical MI swine models. Forty days after graft implantation, swine treated with the engineered cardiac grafts showed significant ventricular function recovery. Irrespective of the scaffold origin or cell recolonization, all scaffolds integrated with the underlying myocardium and showed signs of neovascularization and nerve sprouting. Collectively, engineered cardiac grafts -with pericardial or myocardial scaffolds- were effective in restoring cardiac function post-MI, and pericardial scaffolds showed better structural integrity and recolonization capability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ex vivo assessment and in vivo validation of non-invasive stent monitoring techniques based on microwave spectrometry

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Arauz-Garofalo, Gianluca|||0000-0001-5166-6054
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Amorós García de Valdecasas, Susana
  • Gerez-Britos, Flavio David
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • O'Callaghan, Juan Manuel|||0000-0002-2740-0202
  • Macià, Ferran|||0000-0001-5972-4810
  • Tejada, Javier|||0000-0001-9246-5566
Some conditions are well known to be directly associated with stent failure, including in-stent re-occlusion and stent fracture. Currently, identification of these high-risk conditions requires invasive and complex procedures. This study aims to assess microwave spectrometry (MWS) for monitoring stents non-invasively. Preliminary ex vivo data are presented to move to in vivo validation. Fifteen mice were assigned to receive subcutaneous stent implantations (n = 10) or sham operations (n = 5). MWS measurements were carried out at 0, 2, 4, 7, 14, 22, and 29 days of follow-up. Additionally, 5 stented animals were summited to micro-CT analyses at the same time points. At 29 days, 3 animals were included into a stent fracture subgroup and underwent a last MWS and micro-CT analysis. MWS was able to identify stent position and in-stent stenosis over time, also discerning significant differences from baseline measures (P < 0.001). Moreover, MWS identified fractured vs. non-fractured stents in vivo. Taken together, MWS emerges as a non-invasive, non-ionizing alternative for stent monitoring. MWS analysis clearly distinguished between in-stent stenosis and stent fracture phenomena.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar, the AGTP II trial

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Cámara, Maria-Luisa|||0000-0002-5204-1459
  • Bustamante-Munguira, Juan|||0000-0002-6542-4504
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Avanzas, Pablo|||0000-0002-4958-6108
  • San Román, José Alberto|||0000-0003-0764-0839
  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • De Teresa, Eduardo
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Manito, Nicolás
  • Núñez, Julio|||0000-0003-1672-7119
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Caballero, Ángel
  • Teis, Albert|||0000-0002-4820-0736
  • Lupón, Josep|||0000-0002-5601-9611
  • Brugada, Ramon|||0000-0001-6607-3032
  • Martín, Carlos
  • Silva, Jacobo
  • Revilla-Orodea, Ana
  • Cánovas López, Sergio Juan
  • Melero, Jose M.
  • Cuenca Castillo, José
  • Gonzalez-Pinto, Angel
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac adipose tissue is a source of progenitor cells with regenerative capacity. Studies in rodents demonstrated that the intramyocardial delivery of cells derived from this tissue improves cardiac function after myocardial infarction (MI). We developed a new reparative approach for damaged myocardium that integrates the regenerative properties of cardiac adipose tissue with tissue engineering. In the adipose graft transposition procedure (AGTP), we dissect a vascularised flap of autologous pericardial adipose tissue and position it over the myocardial scarred area. Following encouraging results in acute and chronic MI porcine models, we performed the clinical trial (NCT01473433, AdiFLAP trial) to evaluate safety in patients with chronic MI undergoing coronary artery bypass graft. The good safety profile and trends in efficacy warranted a larger trial. The AGTP II trial (NCT02798276) is an investigator initiated, prospective, randomised, controlled, multicentre study to assess the efficacy of the AGTP in 108 patients with non-revascularisable MI. Patients will be assigned to standard clinical practice or the AGTP. The primary endpoint is change in necrotic mass ratio by gadolinium enhancement at 91 and 365 days. Secondary endpoints include improvement in regional contractibility by MRI at 91 and 365 days; changes in functional MRI parameters (left ventricular ejection fraction, left and right ventricular geometric remodelling) at 91 and 365 days; levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) at 7, 91 and 365 days; appearance of arrhythmias from 24 hour Holter monitoring at 24 hours, and at 91 and 365 days; all cause death or re-hospitalisation at 365 days; and cardiovascular death or re-hospitalisation at 365 days. The institutional review board approved the trial which will comply with the Declaration of Helsinki. All patients will provide informed consent. It may offer a novel, effective and technically simple technique for patients with no other therapeutic options. The results will be submitted to indexed medical journals and national and international meetings. ClinicalTrials.gov: NCT02798276, pre-results.